News Releases

News Releases
Events
Presentations

Year

August 5, 2026

Bioventus Reports Second Quarter Financial Results

Q2 reported revenue of $153.2 million increased 4% Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period Cash from operations

July 29, 2026

Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026

DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday,

June 2, 2026

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference

DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global

May 6, 2026

Bioventus Reports First Quarter Financial Results

Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share Non-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted share in the prior-year period Cash from operations

April 28, 2026

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market opens on Wednesday, May

March 5, 2026

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased

February 24, 2026

Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March

January 6, 2026

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45

November 25, 2025

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference

DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3,

November 4, 2025

Bioventus Reports Third Quarter Financial Results

Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8% Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted share Non-GAAP earnings* of $0.15 per diluted share increased 200% Cash

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 149